Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.33 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.33 |
| ▸ | TACR1 | P25103 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4662901 | 0.87 | CXCR2 (0.33) | CXCR2CXCR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4664643 | 0.87 | CXCR2 (0.33) | CXCR2CXCR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5138943 | 0.87 | CXCR2 (0.33) | CXCR2CXCR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4664676 | 0.85 | CXCR2 (0.34) | NPC1RAB9ACXCR2CXCR1KDM4E | |
| SCHEMBL4664608 | 0.85 | PDK1 (0.32) | NPC1RAB9ACXCR2CXCR1KDM4E | |
| SCHEMBL4666499 | 0.83 | CYP2C9 (0.37) | RAB9ATACR1CTSK | |
| SCHEMBL4664836 | 0.83 | PARP1 (0.35) | CXCR2CXCR1KDM4ECCR5ALDH1A1 | |
| SCHEMBL5114930 | 0.80 | CYP2D6 (0.32) | RAB9ACXCR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5114927 | 0.80 | CYP2D6 (0.32) | RAB9ACXCR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL5106851 | 0.80 | AOC3 (0.32) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113963-A1 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | disclosed |
| US-20060194968-A1 | Cyclic benizimidazoles | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194968-A1 | Cyclic benizimidazoles | VIP, SI, GIPR | NPC1 2772/4885RAB9A 4475/4885CXCR2 4099/4885 |
| US-20080113963-A1 | Cyclic benzimidazoles | VIP, GIPR, SI | NPC1 2631/4885RAB9A 2004/4885CXCR2 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.